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Abstract 
An Examination of Eisenia fetida Coelomic Fluid for Antimycobacterial Activity 
 
Christopher William Meiers 
Master of Science In Biological Sciences 
Minnesota State University, Mankato 
November 2015 
 
 Antibiotic resistance is a growing problem with real world consequences to 
human health and no known solution.  The genus Mycobacterium contains 
several bacteria that can cause serious illnesses including tuberculosis and 
Johne’s disease.  Some of these pathogens also have resistance to several 
antibiotics.  This project sought to find antimycobacterial activity related to the 
phagocytic coelomocytes or soluble substances in the coelomic fluid of the 
earthworm Eisenia fetida.  The phagocytic activity was determined by observing 
the adherence of phagocytes to Mycobacterium smegmatis (strain mc2155) 
bacteria.  The antimycobacterial ability of the coelomic fluid was assessed by 
comparison of viable plate counts after treatment with coelomic fluid extracts.    
The effect of disrupting the microbial flora of the earthworm on these 
antimycobacterial affects was also investigated.  No antimycobacterial activity 
	
was observed in coelomic cells or extracts from earthworms with intact or 
disrupted microbial flora.  However, a trend of increasing coelomic cell 
concentration after treatment of the worm with antibiotics was seen.  There are 
some aspects of the experiment that could be refined to examine the coelomic 
fluid for antimycobacterial activity or antibacterial activity against other problem 
bacteria more precisely.  However, the more fruitful area of research would 
appear to be examining the discrepancy in coelomic cell concentration between 
antibiotic treated and untreated earthworms.   
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1. Introduction 
The growing threat of bacterial resistance to antibiotics is a significant 
concern, as it makes treatment of diseases more challenging, more costly, or 
even impossible (1).  Researchers have searched for new antibacterial drugs in 
increasingly diverse organisms and environments, including terrestrial 
invertebrates (2).  Invertebrates lack the specificity provided by the antibody-
based immunity of vertebrates (3).  Instead, they have a non-specific immune 
system with humoral and cellular aspects (4,5). Investigation into the extracts of 
numerous organisms including terrestrial invertebrates has led to the discovery of 
several antimycobacterial compounds (6,7). 
Earthworm coelomic fluid contains more than 40 proteins with cytolytic, 
proteolytic, antimicrobial, hemolytic, hemagglutinating, tumorolytic, and mitogenic 
activities (8-11).  The coelomic fluid of the earthworm Eisenia fetida andrei has 
antimicrobial activity against Aeromonas hydrophila and Bacillus megaterium, 
both known earthworm pathogens (10,11).  
Another aspect of earthworm innate immunity is the phagocytic activity of 
coelomocytes.  Coelomocytes have two general populations: amoebocytes and 
eleocytes.  The amoebocytes carry out phagocytosis and produce cytokines and 
eleocytes collect contaminants and other stray matter in the coelomic fluid (12). 
Amoebocytes are classified as either hyaline or granular based on their 
appearance (12).  The first step of phagocytosis, cell adhesion, begins with the 
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association with surface receptors of the cell to the particle to be phagocytized 
(13).  If the particle or bacterium is small enough to ingest, phagocytosis 
proceeds.  However, if the particle is too large, such as an invading nematode, 
amebocytes encapsulate the particle and the brown body that is formed moves 
through the coelom toward the posterior body segments, which are detached with 
the particle (11).  After the immune cells of the worm phagocytize bacteria, the 
bacteria clump together and then disperse.  These bacteria are not found in the 
nephridial walls, indicating the phagocytes are able to efficiently breakdown and 
remove bacteria (14).  The phagocytic activity of earthworm coelomocytes can be 
assessed by microscopy.  The amount of coelomic cells adhered to bacteria out 
of the total coelomic cell population can be used as a measure of phagocytic 
activity.  It has been observed that the coelomic cells of Dendrobaena veneta 
show an increased adherence of known earthworm pathogens (Bacillus 
megaterium and Aeromonas hydrophila) over non-pathogenic species (15).  This 
phagocytic ability can be improved by humoral components and opsonins (12).  
An example of this is seen in L. terrestris, where phagocytosis of yeast was 
improved after opsonization with coelomic fluid (16).  It is possible that this 
activity may result from a compound produced by flora of E. fetida, which may be 
able to enhance phagocytosis in its coelomocytes.   
The association of bacteria and phagocytic cells is improved in the 
presence of opsonins.  In mammals, opsonic activity is associated with 
complement and antibodies found in the serum (17).  Beneficial bacteria may 
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also contribute; one study of mouse monocyte-macrophage cells in vitro 
demonstrated increased phagocytic activity in a dose-dependent manner using 
cell-free lactic acid bacteria extract (18).  This indicates that secretions from the 
cells were promoting phagocytosis.  Despite differences between mouse and 
earthworm immune systems, it is possible that this occurs as a result of 
secretions by earthworm bacterial flora as well.  One of the bacteria in the 
earthworm E. fetida is V. eiseniae.  This bacterium present in the nephridia of the 
worm still has no known function.  It is possible that this bacterium or other flora 
may have antimicrobial properties.    
Earthworms interact with numerous soil organisms including species of 
Mycobacterium.  The genus Mycobacterium has had a significant impact on 
human and animal health.  The most high profile disease associated with this 
genus is tuberculosis, caused by Mycobacterium tuberculosis.  In 2013, 
tuberculosis had an incidence rate of 9 million worldwide (19).  Mycobacterium 
leprae, the causative agent of leprosy, has had and still has an impact on the 
human population.  In 2012, there was a prevalence of 189,018 cases and an 
incidence of 232,857 new cases was reported globally (20).  Mycobacterium 
avium subspecies paratuberculosis (MAP) is a veterinary pathogen; it causes 
Johne’s disease, a wasting disease of cattle.  This disease if left untreated, 
causes malabsorption of nutrients in the cow intestine, which can eventually lead 
to death in infected cattle (21).   
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In humans, MAP has been suspected to be responsible for Crohn’s 
disease, a disease with symptoms similar to those of in Johne’s disease (22).  
The Mycobacterium avium complex is a collection of bacteria that cause 
significant human disease.  It is causes an opportunistic infection that produces a 
vast array of symptoms including weight loss, diarrhea, fever, pneumonia, and 
hepatitis.  It is a disease common to immune compromised individuals, in 
particular those in the HIV/AIDS population (23).  
Antibiotic resistance in the genus Mycobacterium and in M. tuberculosis in 
particular is a concern.  M. tuberculosis is able to withstand many broad 
spectrum antibiotics, which is problematic for treatment (24).  Treatment of this 
pathogen includes a multi-drug regimen that can take as long as 6 to 12 months 
to complete and requires fairly strict patient compliance.  The incomplete or 
improper administration of this chemotherapy treatment has led to the 
development of multi-drug resistant strains of the bacterium (25).   In addition to 
mutations that enable resistance to antimicrobial agents, mycobacteria are 
naturally resistant to many common antibiotics.  This is due to the intrinsic 
impermeability of their cell wall that stems from the mycolic acid (26-29).  
However, mycolic acids of the cell wall don’t explain the entirety of the resistance 
seen in Mycobacterium (26).  Synergistic effects have been investigated with 
respect to resistance; research has determined that genes not involved in cell 
wall assembly may work with those involved in cell wall assembly to enable 
resistance to certain broad-spectrum antibiotics (30-32).   
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With MAP infections in cattle, treatment with isoniazid alone or in 
combination with rifampin for the duration of an animal’s life stops the 
progression of Johne’s disease but doesn’t cure the animal.  When treatment is 
stopped, the bacterium again resumes growth and the animal progresses to a 
disease state (33).  Because treatment is not curative, it is rarely undertaken; 
however, it may be considered for animals with exceptional genetic value (34).  
MAP is a difficult pathogen to remove from the livestock environment as infected 
cattle shed large numbers of the bacterium in their feces. MAP can persist in 
black earth for 11 months and manure for a year (35,36).  If cattle graze on grass 
or eat soil contaminated by feces they have the potential to be infected.  
Another cattle pathogen is Mycobacterium bovis, the causative agent of 
bovine tuberculosis (36).  In the United States, the prevalence of this bacterium is 
much lower than that of MAP, as it has been eradicated in all but two states due 
to a surveillance program that started in 1917 (37,38).  This organism has also 
been able to cause tuberculosis in humans, though this is a less common 
occurrence compared to tuberculosis due to M. tuberculosis (39).   
Due to the damaging impact associated with mycobacterial diseases and 
the development of antibiotic resistant strains, new antibiotics and treatment 
regimens should be developed. One can look to organisms that have to deal with 
mycobacteria in their everyday environment.  Since earthworms are residents of 
soil and manure, where MAP is known to persist, specific attention has been paid 
to earthworms (36).  When Lumbricus terrestris earthworms were placed in a 
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highly MAP-contaminated environment and subsequently tested for the 
presence of the bacterium, few of them had culturable bacteria (40).  The 
antimycobacterial activity of the earthworm Dendrobaena veneta stemmed from 
compounds produced by a bacterium that is a close relative of Raoultella 
ornithinolytica, (99% sequence similarity). R. ornitholytica is a suspected 
symbiont present in the midgut of the earthworm.  The authors found the 
bacterium in the intestinal wall of D. veneta worms from multiple different soil 
sources indicating the organism is not merely an acquired soil organism.  The 
metabolites made by the bacterium were postulated to interfere with cell wall 
synthesis as evidenced by the rounded or filamentous forms of the mycobacterial 
cells observed via scanning and transmission electron microscopy (7).  
Investigations of soil bacteria for antibiotic compounds have yielded results in the 
past.  The soil organism Streptomyces griseus produces a compound used to 
derive the anti-tuberculosis drug streptomycin (41).  Thus, the earthworm and its 
bacterial flora may provide a source of antimycobacterial substances.   
Commensal and symbiotic bacterial association with the earthworm has 
been investigated in several instances, though much of the mechanism of 
establishment has yet to be elucidated.  In one study, it was found that there was 
an increase in unrelated bacterial diversity when E. fetida was exposed to E. coli 
0157:H7.  The new bacteria then decreased following the elimination of E. coli on 
day 2 (42).  It was proposed that one of the established gut bacteria, a Bacillus 
species, had an antagonistic relationship with the E. coli, likely secreting a 
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specific antimicrobial substance.  In other words, bacteria antagonistic to E. coli 
including the Bacillus species exist as gut bacteria normally, but at a lower level.  
When a pathogenic challenge is detected, these bacteria increase to a detectable 
level and inhibit the invading bacteria (42).   
In the earthworm E. fetida there is a symbiont, Verminephrobacter 
eiseniae that colonizes the nephridia of the worm.  If this bacterium has a role in 
the earthworm it is unknown, but it is retained and vertically transmitted to their 
offspring cocoons (43,44).  Following hatching of the juvenile worm from the 
cocoon, the worm is unable to acquire the symbiont or other bacteria (44).  Thus, 
when one is assessing the presence or absence of V. eiseniae in an adult worm, 
one can either look to the nephridia of the worm or look to the cocoons produced 
by the worm.   
 The purpose of this study was to determine whether or not V. eiseniae, 
produces antimycobacterial compounds or stimulates phagocytosis.  
Unfortunately many of the Mycobacterium species discussed have slow 
generation times.  It can take up to four months before visible MAP colonies can 
be seen on solid media; others take even longer (40).  Therefore, in order to 
study the effects of substances on any mycobacteria, a common strain of M. 
smegmatis, mc2155, is used for the study of M. tuberculosis and MAP due to its 
genetic similarity and faster generation time (45).   
The purposes of this study were 1) to determine whether or not there are 
antimycobacterial compounds present in the coelomic fluid of Eisenia fetida 
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earthworms and whether there is a vertically transmitted bacterium, which 
affects that ability and 2) to determine whether the phagocytic cells present in the 
coelomic fluid interact with mycobacteria at a higher level when there is vertically-
transmitted bacterium present in the worm. 
The hypothesis for this study was: The coelomic cells and fluid of the 
earthworm E. fetida have antimycobacterial properties, which may or may not be 
influenced by the presence of V. eiseniae.  If true, the treatment of M. smegmatis 
with E. fetida coelomic fluid should show a decrease in bacterial concentration. 
Also, phagocytic activity should be apparent based on adherence of phagocytes 
to M. smegmatis.  If symbiotic bacteria have an affect on phagocytic coelomic 
cells, the amount of cells interacting with M. smegmatis should be positively or 
negatively with the loss of the symbiont.   
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2. Literature Review 
Overview 
The overall goal of this project was to assess the earthworm Eisenia fetida 
for antimycobacterial activity.  In order to understand why this project was 
undertaken, information on the specifics surrounding the earthworm, the genus 
Mycobacterium, and antibiotic discovery need to be elucidated.  For E. fetida, 
anatomy, immune function, and symbiotic bacteria of the earthworm will be 
discussed.  For the mycobacteria, common pathogenic species and antibiotic 
resistance mechanisms will be analyzed.  Natural sources of antibiotics will also 
be examined.  These areas will provide a basis for understanding how new 
antimycobacterial compounds might be discovered in E. fetida.   
Mycobacterium and Antibiotic Resistance 
The genus Mycobacterium is largely composed of saprophytic soil 
microorganisms that are often associated with sphagnum moss, surface and 
drinking water, and soil with organic materials (36).  This genus, composed of 
>50 species, is related to Streptomyces and Actinomyces.  There are several 
successful pathogens in Mycobacterium including Mycobacterium tuberculosis, 
Mycobacterium leprae, and Mycobacterium avium subspecies paratuberculosis 
the causative agents of tuberculosis, leprosy, and Johne’s disease, respectively 
(46).  The saprophytic organisms in this genus are slower growing compared to 
many other bacteria. However, most pathogenic mycobacteria take weeks to 
months to form colonies, and one has yet to be grown in culture, therefore since 
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the saprophytes tend to only take 7 days to form colonies on a plate they are 
desirable for their use in research (47,48). Mycobacterium tuberculosis can take 
2 to 4 weeks and Mycobacterium avium subspecies paratuberculosis colony 
formation takes 3 months or more (49,50).  
These organisms are nonmotile, nonsporulating, weakly Gram-positive, 
acid-fast bacilli, which appear as straight or slightly curved rods.  They are 1 to 4 
µm in length and 0.3 to 0.6 µm wide (51).  These bacteria have mycolic acids that 
are critical to the cell wall (52).  The waxy phenotype of the cell wall conferred by 
these acids results in: acid-fast staining, hypdrophobicity, and resistance to 
drying, acidity/alkalinity, and many antibiotics.  Mycolic acids have 
immunostimulatory properties for the host immune system (53).  These also allow 
for rapid diagnosis of mycobacteria by way of the acid-fast stain or Ziehl-Neelsen 
that identifies bacteria possessing mycolic acids (acid-fast) versus those that 
don’t (non-acid-fast) (based off a translation in Kazda et. al.) (36,54,55).  Using 
this technique one can easily detect acid-fast mycobacteria in sputum samples.   
Much of the antibiotic resistance of Mycobacterium is an intrinsic 
resistance based primarily on the impermeability of the cell wall (26,27). No 
horizontal transfer via plasmids or transposons has been observed: thus, these 
resistances most likely arise by chromosomal mutations that occur as a result of 
selective pressure from antibiotic use (56). However, it has been found that cell 
wall composition doesn’t entirely explain the observed antibiotic resistance (26).  
Thus, synergistic effects related to genes not involved in cell wall assembly that 
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enable resistance to some broad-spectrum antibiotics have been investigated 
(30-32).  These include modification of drug targets such as ribosomal RNA, 
chemical modification of the antibiotic such as the acetylation of amine groups in 
aminoglycosides, enzymatic degradation of drugs such as β-lactamase activity, 
molecular mimicry of drug targets such as the production of MfpA as a decoy 
sequence for fluoroquinolones, and the use of efflux pumps to remove antibiotics 
from the bacterium (57-63).     
Mycobacterium tuberculosis 
The most well known member of this genus, Mycobacterium tuberculosis, 
causes the lung disease tuberculosis (TB). The symptoms of pulmonary TB 
include chronic cough, sputum production, appetite loss, weight loss, fever, night 
sweats, and hemoptysis (64).  Other less common bacteria in this genus 
including Mycobacterium africanum, Mycobacterium canetti, Mycobaterium bovis, 
Mycobacterium caprae, Mycobacterium myroti, and Mycobacterium pinnipedii 
can also cause tuberculosis (36).  In 2013 there was an incidence of 9 million 
tuberculosis cases worldwide, that same year 1.5 million people died from the 
disease (19).   
In more than 90% of cases of this disease, the bacterium is contained as 
an asymptomatic latent infection (65).  Transmission of this bacterium is typically 
through contaminated aerosol from an infected person; however, it can also be 
shed in feces, urine, and other excretions and secretions (36).  Without 
treatment, approximately 5-10% of TB infected individuals will develop active TB 
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(66). A latent infection is associated with a lower risk of reinfection after 
another exposure (67).  Conversely, if progression to active infection occurs and 
is treated, there is an increased risk of a second episode of TB on reexposure 
(68,69).  Diagnosis of the latent form of this disease is typically done by a 
tuberculin skin test or an interferon-gamma release assay (65).  The tuberculin 
skin test or Mantoux tuberculin test is performed by injecting 0.1mL of tuberculin 
purified protein to the forearm; a further swelling of the injection site indicates an 
inflammatory action of T helper lymphocytes.  This means the individual is likely 
infected with the bacterium, however a false positive can result if they have been 
infected with mycobacteria including M. tuberculosis previously; thus, a 
confirmation may be undertaken to confirm the diagnosis (70).  Active TB 
diagnosis is typically performed via sputum microscopy and culture in a liquid 
medium with associated drug susceptibility testing (65).  However, a new 
molecular test, Xpert MTB/RIF, detects M. tuberculosis complex within 2 hours 
using real time PCR to amplify a specific mutated sequence of the M. 
tuberculosis rpoB gene that indicates rifampin resistance. This method is a more 
sensitive method than smear microscopy (71-73).   
One of the key aspects of M. tuberculosis pathogenicity is the invasion of 
macrophages of immunocompetent individuals (74).  This bacterium is able to 
use several strategies to evade destruction by macrophages.  These include 
disruption of: phagosome-lysosome fusion, recruitment of hydrolytic lysosomal 
enzymes, reactive oxygen and nitrogen species production, antigen presentation, 
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and MHC class II expression and trafficking, autophagy, and apoptosis (74).  
Entry into the macrophages requires recognition of the bacterium by several 
opsonic and non-opsonic receptors (75).  The non-opsonic method uses pattern 
recognition receptors (PRRs), which recognize pathogen-associated molecular 
patterns (PAMPs) (76).  In the case of opsonic uptake of M. tuberculosis, there is 
recognition of coated bacteria with complement factors, antibodies, and/or 
surfactants (77).  However, most agree that ingestion of the bacterium occurs by 
non-opsonic means in the early stages of infection (77-80).  Non-opsonic entry 
into the macrophage has been found to be associated with higher intracellular 
survival than opsonic entry; this suggests specific receptors need to be used to 
disrupt phagosome-lysosome fusion (78).   
Immune CD4+ T lymphocytes protect against TB, however some research 
indicates the participation of CD8+ T lymphocytes (81-84).  The risk of developing 
active TB increases soon after infection with HIV, due to a lower population of 
functioning T lymphocytes (85).  In 2013 1.1 million were HIV positive of a total 
incidence of 9 million (19).  Once CD4 cell counts reach less than 200 per mm3, 
the presentation of TB becomes atypical.  Subtle infiltrates, pleural effusions, 
hilar lymphadenopathy, and other forms of extrapulmonary TB appear in up to 
50% of patients (65).  When CD4 counts reach less than 75 per mm3, pulmonary 
evidence may be lacking, and disseminated TB manifests as a nonspecific, 
chronic febrile illness with bacterial distribution to other organs.  In these 
instances bacteremia is more frequent.  This results in high early mortality.  The 
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HIV positive status is also associated with multiple M. tuberculosis strain 
involvement (86).   
Treatment of TB is not simple.  For latent TB, the regimen is isoniazid 
alone for 9 months in a healthy individual or longer for HIV-infected individuals 
(87,88).  For active TB, a four-drug regimen of isoniazid, rifampin, pyrazinamide, 
and ethambutol is effective in 90% of cases in which no drug resistance is 
detected (89).  The 6-month treatment program requires an initial 2 months of 
treatment with all four antimycobacterial drugs followed by 4 months of isoniazid 
and rifampin.  If risk factors for relapse (including cavitation, extensive disease, 
immunosuppression, or a positive sputum culture at 8 weeks) are present, the 
therapy can be extended up to 9 months (65).  Barriers to the efficacy of this 
regimen include: inconsistent drug quality, treatment interruptions due to side 
effects, toxic effects, pharmacokinetic interactions (such as with antiretrovirals for 
HIV), and compliance issues due to the length of treatment (65,90).  In an 
attempt to reduce the therapy to a more manageable 4 months, some trials have 
added or substituted fluoroquinolones or added higher doses of rifamycins (65).   
A global report on TB by the WHO in 2014 estimated that the proportion of 
multi-drug resistant TB (MDR-TB) was between 14 and 28%, of these, 9% were 
extensively drug resistant TB (XDR-TB) (19).  Eighty-four countries that have 
reported extensively resistant strains that have resistance to fluoroquinolones 
and the injectable drugs: kanamycin, amikacin, and capreomycin (89,91,92).  
Improper use of anti-TB drugs including using monotherapy and adding a single 
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drug alongside currently failing drugs has favored the cultivation of these 
resistant mutants via selective pressure (65).  Unfortunately, it is estimated that 
only 10% of cases of MDR-TB are currently diagnosed worldwide, and only half 
of these receive appropriate treatment (89,91,92).    
MDR-TB is typically treated using either standardized treatment or 
individualized treatment once the empirically determined resistance pattern of the 
bacterium becomes known (65).  These regimens typically require combination 
drugs from five groups of first-line and second-line drugs, which need to be used 
for 20 months or 30 months for those who have had MDR-TB previously (65,93).  
Another treatment, the Bangladesh regimen, is a 3-stage regimen that involves a 
shorter treatment time of 21 months with fewer adverse effects and more positive 
outcomes including some showing no identifiable bacteria at 3 months.  This 
treatment is a standardized treatment based on the resistance pattern observed 
in a sampling of the population (94).  This allows for less extensive 
hospitalization and less time waiting on individual culture tests.  XDR-TB is a 
greater challenge to diagnose and treat; it has been associated with an extremely 
high death rate among HIV-infected individuals (95,96).   
Some new drugs have shown some activity against MDR and XDR-TB 
and are being investigated further; several of these drugs have new mechanisms 
of action against M. tuberculosis.  These include new fluoroquinolones that inhibit 
topoisomerase IV and DNA gyrase, new nitroimidazoles that inhibit mycolic acid 
synthesis in replicating TB and generate highly reactive nitrogen radicals in non-
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replicating TB, bedaquiline that inhibits ATP synthase, new oxazolidinones that 
inhibit translation by blocking binding at the A site of peptidyl transferase center 
of the mycobacterial ribosome, and SQ109 that inhibits the MmpL3 transporter, 
necessary for the integration of trehalose mycolate,into the cell wall (65).  One 
three-drug treatment including moxifloxacin, pyrazinamide, and PA-824 showed 
14-day bactericidal effect similar to that of the standard four-drug therapy (97).   
The Mycobacterium bovis Calmette-Guérin (BCG) attenuated vaccine is 
commonly used in areas where TB is endemic (65).  The prevention efficacy of 
this vaccine is approximately 50% (98).  The vaccine is not appropriate for use in 
immunosuppressed individuals as it has the potential to cause a fatal 
disseminated infection (65).  The restrictions of this vaccine have led others to 
investigate other options; over 30 vaccines are in development (99).  Another TB 
vaccine uses Mycobacterium microti, which has the same level of efficacy (100).  
Unfortunately, the use of these vaccines undermines the efficacy of tuberculin 
skin testing (66).   
Mycobacterium leprae 
Leprosy, caused by Mycobacterium leprae, was first described in 460 BC 
by Hippocrates, though archaeological evidence from Egypt suggests indicates it 
has been around since 4000 BC (48).  Leprosy, also called Hansen’s disease, 
has an array of symptoms including skin lesions; growths on the skin; thick, stiff, 
or dry skin; severe pain; numbness on affected areas of skin, muscle weakness 
or paralysis, eye problems including eventual blindness, enlarged nerves, and 
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ulcers on the soles of feet (101).  Like many others in the genus 
Mycobacterium, M. leprae has a long incubation period and it can take from 5 to 
20 years to appear (20). This disease is not just one of historical record; in 2012 
there was a prevalence of 189,018 cases, with 232,857 new cases globally (20).   
Even though this disease has been around since early-recorded history, 
the causative agent, M. leprae, wasn’t determined to be the cause until 1875 
(102).  This proved to be a difficult pathogen to grow outside of the infected host; 
it wasn’t done until 1960 when it was successfully grown in mouse footpads.  It 
has yet to be cultured in vitro (103).  A more recent discovery is that another 
species, Mycobacterium lepromatosis, also causes leprosy (104).   In the 1960s, 
a multidrug regimen including dapsone, rifampicin, and clofazimine was 
developed after resistance to dapsone alone occurred (20).  Fortunately, at this 
point no resistance to this multidrug treatment has been reported (20).   
It is generally understood that transmission of this disease is airborne and 
by direct skin contact by an infected individual (36).  This bacterium has also 
been isolated from feral nine-banded armadillos, which indicates that infected 
individuals aren’t the only source of this pathogen.  It has also been postulated 
that polluted drinking water may be a source (36).  Some support for this was 
seen in Indonesia, where PCR testing was performed for M. leprae DNA.  These 
tests indicated a higher prevalence of leprosy amongst individuals that used 
contaminated water for bathing and washing clothes or dishes (105). 
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Mycobacterium bovis 
Mycobacterium bovis is a cattle pathogen, the causative agent of bovine 
tuberculosis (36).  This is currently of lower concern than other cattle pathogens 
as it has been eradicated in all but two states due to an eradication program that 
started in 1917 (37,38).  This organism has also caused tuberculosis in humans, 
but is a much less common occurrence compared to that caused by M. 
tuberculosis (39).  However, disseminated infections in individuals with 
immunodeficiencies can result from vaccination with BCG.  As such, it has been 
seen that areas with large populations of AIDS patients are showing these 
complications to the vaccine (106).  Unfortunately, treatment of adverse reactions 
and disseminated BCG infection is still controversial, as the multiple strains with 
different resistance patterns are used, and there is no standardized treatment at 
present (107-109).  Since multiple strains of BCG are used in the creation of this 
vaccine, the treatment of each strain needs to be done according to the strain’s 
susceptibility pattern to different antituberculosis drugs (110).   
Mycobacterium avium subspecies paratuberculosis 
There are several diseases associated with Mycobacterium avium 
subspecies paratuberculosis (MAP); some are veterinary diseases, while others 
are found in human populations.  A German veterinarian Heinrich Johne first 
described MAP as the causative agent of Johne’s disease in 1895 (111).  Several 
other Mycobacterium avium subspecies are also associated with disease.  These 
include M.a. hominisuis, which causes avian mycobacteriosis in humans, pigs, 
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cattle, and other animals, M.a. silvaticum, which causes disease in wild and 
domestic birds, and M.a. avium, the causative agent of avian tuberculosis in 
birds, domestic pigs, cattle, and other mammals (36). The chronic inflammation 
of Johne’s disease results in malabsorption of nutrients in the intestine, which 
can lead to death in the cow (8).   
Johne’s disease is a significant problem in agriculture with an estimated 
cost between $200 and $250 million based on lost dairy production (112).  
Another estimate puts the costs at closer to $1.5 billion (113).  These costs are a 
result of direct and indirect losses.  Direct losses include mortality of infected 
animals and the resulting decreased slaughter value, decreased milk production 
in quantity and quality resulting from mastitis, decreased pregnancy rate and 
postpartum complications, poor food conversion in clinically or sub clinically 
infected animals, decreased productive age in infected animals, and increased 
predisposition to other chronic diseases.  Indirect losses include unrealized future 
income by breeding animals being prematurely culled, increased expenses from 
idle production, increased expenses for herd replacement, expenses for 
diagnostic testing for MAP and associated veterinary care for ill animals, 
expenses for a control program, lost genetic value of desirable animal traits, 
expenses associated with trade restrictions, and lost reputation of a farm with 
infected animals (114).  
Due to the high losses associated with this disease, a means of 
successful treating of cattle would be desired.  Treatment with isoniazid alone or 
	 20	
in combination with rifampin for the duration of an animal’s life can stop the 
progression of MAP but doesn’t cure the animal.  When treatment is stopped, the 
bacterium again progresses to the disease state (33).  Because treatment is not 
curative, it is rarely undertaken, although it may be considered for animals with 
exceptional genetic value for the breeding life of the animal (34).  MAP is also a 
difficult pathogen to remove from the environment of the cattle.  Infected cattle 
can shed the bacterium in their feces; the bacterium can persist in black earth for 
11 months and manure for a year (35,36,115).  As such, MAP can be found in 
soil, manure, and surface water as a result of cattle fecal contamination (116-
118).  Some MAP bacteria have been found in free-living amoebae in fields, 
which indicates they may persist due to their ability to infect the amoebae (119).  
Due to the ubiquity of the bacterium in the farm environment, it is easy for 
uninfected cattle to acquire the pathogen simply from grazing and drinking.  
Without a proper curative treatment, the cost of an MAP infection in a herd of 
cattle can be devastating to the financial success of the farm.   
Organisms belonging to the Mycobacterium avium complex (MAC) cause 
opportunistic infections with a vast array of symptoms including weight loss, 
diarrhea, fever, pneumonia, and hepatitis.  The MAC cause a disease common to 
immune compromised individuals, particularly those in the HIV/AIDS population 
(23).  It can cause chronic lung disease in immunocompetent individuals and  
disseminated disease in those with AIDS (120).  This disease has a similar 
resistance pattern to other mycobacteria.  A multidrug regimen including 
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macrolides has been demonstrated to be the most effective treatment 
(121,122).  Unfortunately, the newer regimen has been found to have increased 
adverse effects including drug toxicities exacerbated by interactions with other 
drugs (123).  Also, despite an improved treatment success, it is still not deemed a 
satisfactory regimen (120).  MAC has also been found to be a rising problem in 
those with functioning immune systems (124).   
A human disease with a suspected mycobacterial origin is Crohn’s 
disease (CD), a chronic inflammation of the bowel in humans.  It can affect those 
with a normal immune system; it is also suspected that MAP causes this disease 
(22). Some of the support for MAP as an etiologic agent of CD includes: 
1. Examination of diseased intestinal tissue from Crohn’s patients and 
Johne’s diseased intestinal tissue show similarities.  This led researchers 
to conclude they may be caused by the same bacterium (125).  Both of 
these diseases share symptoms such as weight loss and chronic diarrhea, 
they also both produce tissue with granulomas and inflammatory action in 
the small bowel and the colon (126).  Unfortunately, detection of MAP in 
human patients with Crohn’s was unsuccessful in these studies.  
2. Tests for the MAP-specific protein tyrosine phosphatase A have shown a 
significant increase in CD patients in comparison to the control group 
(127).   
3. Several studies have detected MAP at a higher frequency in the blood and 
tissue of CD patients than in those of unaffected individuals (128-131).   
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4. MAP isolated from a CD patient was inoculated into a young goat, 
which subsequently acquired Johne’s disease, this indicates that the 
transference of the inflammatory symptoms after infection (132).  
 The etiology of the disease remains unknown but it is typically understood 
to involve genetic, environmental, and immune factors coupled with increased 
inflammatory action (133).   
Proponents of a bacteria-associated disease have postulated that 
pathogenesis occurs when a genetically susceptible host ingests the bacterium.  
The organism enters the intestinal wall via disrupted epithelium.  MAP then 
stimulates an immune response perpetuated by immune reactivity to the 
organism.  The bacterium is then ingested by intestinal macrophages, the 
bacteria have been observed in a different form devoid of a cell wall (spheroplast) 
(134).  Once inside the bacterium can exist in a latent form for years, with the 
potential to produce several inflammatory mediators that have been observed in 
CD affected individuals (135).  These mediators also stimulate naïve T cells to 
differentiate into T-helper 1 cells, which stimulate macrophages to secrete further 
inflammatory mediators.  These cytokines activate natural killer cells, which 
produce the tissue damage common to CD (136).  Another observation that 
supports an association between MAP and CD is that peripheral blood 
mononuclear cells (PBMCs) isolated from CD patients could be induced to 
produce T cells and secrete inflammatory cytokines such as TNF-α and IL-10 
when incubated with MAP (137).   
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The NOD2/CARD15 gene is one associated with the development of 
CD (135,138).  Individuals with mutations in this gene have a malfunctioning 
innate response to bacterial infection; thus, it may be associated with a poor 
clearing of intracellular MAP.  This is a proposed connection for CD and MAP 
causation (139).  Some supporting evidence of this is shown in PBMCs from CD 
patients who have NOD2 mutations, thus they lack proper recognition of MAP 
(140).  Some support for this idea is given in the identification of CARD15 single 
nucleotide polymorphisms; this genetic type in cattle has shown a higher 
susceptibility to MAP infection (141).   
As was stated previously, infected cattle can shed MAP containing feces, 
which can contaminate soil and surface water (116-118).  Contaminated manure 
from cattle can also contaminate crops and drinking water, which can contribute 
to human exposure (142,143).  One study has shown that MAP bacteria are able 
to form biofilms in water systems for several weeks even under high flow 
conditions (144).  In addition to these forms of contamination, dairy products 
including pasteurized milk and milk powder for infant formula can also harbor 
MAP, which may expose individuals to MAP bacteria (145-147).  Though there 
hasn’t been conclusive evidence that the consumption of MAP in these has lead 
to the development of CD (148).  There has been evidence of a systemic 
infection with the detection of MAP in breast milk of CD patients whereas 
lactating control individuals didn’t have the bacterium (149).  Despite the 
presence of MAP in breast milk, no evidence of vertical transmission to offspring 
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has been observed (150).  It has been postulated that MAP can exist in 
systemic and local forms (130).  It has also been postulated that soil may serve 
as a source of mycobacterial infections including M. avium infection (151-154).  
As it stands there has been difficulty in detecting MAP in the blood and 
tissues of immunocompetent CD patients via direct observation (155).  However, 
there has been some success in culturing the bacterium from the intestines of 
several Crohn’s disease patients (132).  Some research supports the idea of a 
morphologic change to a smaller spore morphotype that survives heat and other 
stressors, which may allow for survival in the host and the environment (156). 
This may also explain the difficulties in culturing of the organism, this challenge in 
culturing continues to contribute to the debate as to whether MAP is a pathogen 
causing damage to the host or is just a transient bacterium associated with the 
environment (126).  Some research indicates bacterium has a modified cell wall 
when present in humans, thus it no longer has an acid-fast character (157).  It is 
challenging to isolate MAP DNA from soil, as humic acids and other organic 
material often affect its extraction.  Instead either denaturing gradient gel 
electrophoresis or T-RFLP alongside cloning and sequencing is often performed 
(158-160).  Due to challenges culturing the bacterium, PCR for IS900, an 
insertion sequence specific to MAP is commonly used for detection of the 
bacterium (116,117,161,162).   
The evidence linking the relationship between MAP and CD is conflicting, 
for example, as some phenotypes of CD are not present in Johne’s including 
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fibrosis, fistulae, fissures, and pseudopolyps (163).  It has also been shown 
that farmers consistently exposed to MAP-infected cattle have shown no higher 
prevalence of CD (164).  Another somewhat confusing observation is that MAP 
presence is decreased in immunosuppressed individuals.  One explanation is 
that MAP doesn’t cause CD, but is able to thrive in the immune dysfunction and 
inflammatory environment caused by CD (126).  Based on current evidence it is 
no defined etiology of CD by MAP is possible.   
Mycobacterium smegmatis as a Model Organism 
Mycobacterium smegmatis is a common environmental bacterium found in 
soil, dust, water, animal tissue, and human genital secretions (165).  It was first 
isolated from syphilitic chancres in 1884 by Sigmund Lustgarten (166).  It was 
later determined that M. smegmatis is not associated with disease when it was 
found in normal human genital secretions (smegma) (translation from article by 
He and De Buck) (167,168).  This bacterium has only rarely has acted as a 
pathogen; these are typically disseminated infections in soft tissues, usually 
associated with immunosuppression (165,169-171).  As with other mycobacteria, 
M. smegmatis is resistant to some antibiotics including isoniazid and rifampin, 
however it is susceptible to ethambutol, imipenem, doxycycline, 
sulfamethoxazole, amikacin, and ciprofloxacin (171).  It also has cell wall similar 
to its pathogenic relatives such as M. tuberculosis, MAP, M. leprae (168). The 
similarities don’t end at its cell wall; the genome of M. smegmatis has homology 
to those relatives, which makes it ideal for studying those pathogens (45).   
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Due to these similarities, this organism is commonly used to study 
pathogenic mycobacteria (172).  M. smegmatis is a faster-growing bacterium (3 
to 4 hr. doubling time) with a fully sequenced genome, making it a useful model 
organism The mc2155 strain is commonly used (168,173).  
Natural Sources of Antimicrobial Compounds 
Antimicrobial resistance in bacterial populations is a significant problem.  
The treatment of disease becomes more challenging, more costly, or impossible 
in these instances (1).  Many currently available antibiotics have been derived 
from natural sources including terrestrial plants, microorganisms, vertebrates, 
and marine invertebrates (174). In one survey, approximately 66% of 148 were 
either natural products or derived from a natural product scaffold (175).   
One of the most famous antibiotics is penicillin, a compound that was 
discovered by Alexander Fleming in 1928.  He observed that the fungus 
Penicillium notatum secreted a substance that inhibited the growth of 
Staphylococcus aureus (176).  Therapeutic use of the drug wasn’t fully realized 
until the first successful treatment of a patient with streptococcal septicemia in 
1942 (177).  Penicillin (which acts on enzymes referred to as penicillin-binding 
proteins (PBPs)) contains a beta-lactam ring that interrupts the formation of 
peptidoglycan in bacterial cell walls (178).    
 An antibiotic more germane to the subject at hand is streptomycin, the first 
drug used to remedy tuberculosis (179).  Selman Waksman, a soil microbiologist, 
isolated this antibiotic.  It was found to be the most potent antimycobacterial 
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substance of 10 other candidates (180,181).  This compound was isolated 
from the bacterium Streptomyces griseus by one of Waksman's collaborators 
Albert Schatz (182).  This drug acts as a protein synthesis inhibitor and works by 
binding the 16S rRNA of the 30S subunit of the bacterial ribosome (183).  
However, bacteria gain resistance to this antibiotic via mutations of the ribosomal 
proteins (184).  
 As mentioned above, some terrestrial invertebrates have been examined 
for antimicrobial activity.  Limited specific attention has been focused on these 
invertebrates in regards to antimycobacterial activity.  Most studies are indirect 
and linked to the fact that MAP is able to persist in soil and feces, which 
earthworms can inhabit (36).  A few studies have examined the interaction 
between mycobacteria and earthworms.  In one study, Lumbricus terrestris 
earthworms were placed in a highly MAP contaminated environment; these 
worms were then tested for the presence of the bacterium and a low proportion of 
them had culturable bacteria (40).  However, this study did not elucidate the 
mechanism the observed failure of MAP to colonize the worm.  Another study 
found that antimycobacterial activity of the midgut of the earthworm Dendrobaena 
veneta stemmed from a close relative (99% sequence similarity) of Raoultella 
ornitholytica.  It has been postulated that this suspected symbiont produced 
metabolites that disrupted cell wall synthesis.  This was evidenced in rounded or 
filamentous forms of mycobacterial cells when observed using scanning and 
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transmission electron microscopy.  R. ornithinolytica is consistently found in 
the intestinal wall of worms from several different soil sources (7).   
Eisenia fetida and its Symbiont Verminephrobacter eiseniae  
Several pathogens are associated with soil: opportunistic or emerging 
pathogens present in the soil microbiota such as Aspergillus fumigatus spores 
that may be inhaled causing disease and soil-based diseases caused by 
pathogens that exist in the soil naturally or enteric pathogens that enter via 
human or animal excrement such as Clostridium tetani, Bacillus anthracis, and 
Clostridium perfringens (185).  Current human waste disposal practices may 
allow the accumulation of large concentrations of enteric pathogens into soil that 
can contribute to some of these exposures (186).  Several outbreaks have 
stemmed from water exposed to contaminated soil (187-190).  Other common 
outbreaks of disease are related to fecal-contaminated soil in produce (190-192).  
MAP has been detected in soil as well as M. leprae indicating soil may be a 
reservoir for M. leprae (154,193,194).  Contamination of this soil also occurs by 
fecal contamination by animals and survival for up to a year or longer due to 
association with amoebae or other protozoa (119).  Soil bacteria also interact 
with various invertebrates including earthworms (195-199).  In the case of 
earthworms, most of these bacteria go through the digestive tract and are 
excreted (200).  
The earthworm Eisenia fetida, from the family Lumbricidae, typically 
inhabits areas rich in organic material such as manure, horticultural land, and 
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forests with large amounts of leaf liter (201).  These annelids are commonly 
used in vermicomposting and ecotoxicological studies.  They are also used for 
comparative biochemistry, physiology, and immunology studies (202).  The worm 
is epigeic, meaning it exists in the top layer of its habitat.  The top layer of soil is 
rich in decaying organic matter; this layer also contains a high variability in 
microbiota (202).  As earthworms digest organic matter, their digestive system 
disintegrates, grinds, and degrades this material.  These activities can be 
affected by the activity and concentration of beneficial and pathogenic microbes; 
these can include beneficial and pathogenic fungi, actinomycetes, and bacteria 
(203).  Microorganisms in the digestive system are the most important to 
earthworms with regard to the degradation of organic matter (204).  In addition, 
organisms in earthworm intestines including Bacillus, Pseudomonas, Klebsiella, 
Azotobacter, Serratia, Aeromonas, and Enterobacter species are plant growth 
promoters, free-living nitrogen fixers, and phosphate solubilizers that are 
deposited by earthworms in their passage through the soil (204-207).  The results 
of one study on intestinal microbial diversity revealed that the gut of E. fetida 
housed 21 taxa of bacteria (208).   
Symbiotic bacteria have many roles in the lives of their hosts; these 
include development, nutrition, reproduction, speciation, antimicrobial defense, 
and immunity (209-219).  Obligate symbionts show very specific interactions with 
the host’s cells in numerous invertebrates.  They are transmitted vertically from 
the mother to eggs or embryos.  The bacteria then go on to colonize the progeny 
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during their development (209).  Mutualistic bacteria have been able to 
develop such that they don’t harm their host, but confer beneficial attributes to 
the host; this symbiosis is sometimes necessary for bacterial survival (220).  In 
one well-studied bacterial symbiosis, Vibrio fischeri allows the squid Euprymna 
scolopes to mask its position from predators by using V. fischeri bioluminescence 
to hide its shadow (221).  Another example of a highly beneficial relationship is 
that of reef-building corals and photosynthetic algae.  In this instance the algae 
perform photosynthesis, producing glucose, glycerol, and amino acids.  In some 
instances the growth and formation of reefs is only possible with algae present in 
the coral (222).   
 Numerous bacterial symbionts of various earthworm species have been 
identified.  Often these bacteria are identified via isolation on selective media and 
genetic identification (223-228).  Identification is often performed indirectly by 
sequencing the contents of the worm, as some are not cultivatable at present 
(228).  Suspected symbiotic microbes present in the earthworm gut can be 
identified by their genome; however, they need to be distinguished from soil 
organisms that transit through the digestive tract (208).  These microbes have 
been found to be highly beneficial to the earthworm health.  In one report, young 
hatched from sterilized E. fetida cocoons were unable to reach sexual maturity 
when raised in sterilized soil unless protozoa were added to their food (229).   
In E. fetida, the first described obligate symbiont doesn’t lie in the intestine 
but in the nephridia of the worm.  The nephridia are paired organs with three 
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loops; these are present in every segment of the earthworm, there are 200 in 
total.  These take in fluid that comes from the coelom, a cavity surrounding the 
intestine of the worm (230).  The ciliated mouth of the nephridia, called the 
nephrostome, takes in this coelomic fluid from the coelom and blood from the 
vessels. After passage through the different loops of the nephridium, nitrogenous 
waste is excreted through the nephridiopore.  The nephridia also have an 
osmoregulatory function (230).  The symbiont present in the ampulla (the second 
loop) of the nephridia was first identified in 1926 by microscopic observation 
(translation in Davidson et. al.) (44,231).  These bacteria were first genetically 
identified as belonging to the genus Acidovorax (232).  A closer examination via 
16S rRNa analysis of this bacterium identified it as being in a newly identified 
genus and species Verminephrobacter eiseniae (233).  The function of this 
bacterium in the worm remains unknown; one proposed purpose has been 
proteolysis to allow better absorption and amino acids (translation from Lund et. 
al.) (234,235).  This may increase nitrogen excretion by earthworms, which 
releases nitrogen into the soil (232).   
While the function of the bacterium has been thus far ambiguous, the 
colonization of the symbiont has been well investigated.  These bacteria are 
transferred from adult worms to their offspring in egg capsules during mating.  It 
was also demonstrated that it wasn’t acquired from the environment (44).  The 
bacteria are secreted through the clitellum after exiting the bladder, the third loop 
of the nephridia; these symbionts then enter the albumin of the egg capsule (43).  
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A model for colonization of the earthworm embryo in the cocoon has also been 
elucidated.  The work of Davidson and her collaborators has shown that 
colonization of the embryonic nephridia occurs when the nephridial canal 
matures in a segment, this releases an attractant to draw in the V. eiseniae 
bacteria (236).  Another study looked into some V. eiseniae’s components 
necessary for motility and colonization of embryonic nephridia.  It was found that t 
flagellar motility and type IV pili were necessary for proper colonization.  The 
twitching motility afforded by pilB and pilC is necessary for migration from the 
albumin of the cocoon through the colonization pore and duct, the nephridiopore, 
and the bladder.  The flagellar motility conferred by flgK and flgL genes is 
necessary for the final migration from the bladder to the ampulla where the 
bacterium binds (237).   
A further investigation of the nephridia and the symbiont has shown there 
are additional bacteria involved in the process; these include novel 
Microbacteriaceae and Flexibacteriaceae members and Hebraspirillum species.  
The V. eiseniae bacterium, Microbacteriaceae, and Flexibacteriaceae bacteria 
were present in both the cocoon and the adult nephridia; however, the 
Hebraspirillum bacteria were at a lower than detectable level in the cocoon, and 
may have been acquired from bedding or were in a lower than detectable level in 
the cocoon.  It was hypothesized that the presence of these bacteria other than 
Hebraspirillium protects the earthworm embryos during development (43).  This 
was supported by an observation of suppressed growth of Herbaspirillum 
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bacteria later in development, as it has a pathogenic role in the earthworm.  
Another study has investigated Verminephrobacter species in multiple 
earthworms. Nineteen of 23 lumbricid earthworms had one of these symbiont 
species present.  Sequencing of 16S rRNA and rpoB genes revealed that the 
genetic similarity of symbionts corresponded to genetic similarity of the 
earthworm host species, indicating coevolution (235).  Despite ambiguity as to 
the function of the symbiont, it is clear that it is beneficial for the bacterium, the 
host, or both, as E. fetida and other related earthworms conserve the bacterium. 
Earthworm Immunity 
In order to evaluate the antimycobacterial activities of earthworms, 
knowledge of their immune system is necessary.  Invertebrates, including 
earthworms, lack the antibody-based specific immunity of vertebrates (3).  
Instead, they have an innate immunity with humoral responses mediated by 
pattern recognition receptors and phagocytic responses including brown body 
formation.  These are associated with the coelomic fluid in the worm (4,45).  In 
addition to these, earthworms have skin consisting of an epidermis and a thin 
cuticle containing mucopolysaccharides that act as an antimicrobial barrier 
(238,239).  The epidermis is composed of a layer of epithelial cells, basal cells, 
and secretory cells.  These basal cells help in the process of wound healing and 
graft rejection, and often exert phagocytic activity (240,241).   
The coelom is a cavity filled with coelomic fluid.  This fluid contains cells 
called coelomocytes; the transport of these cells and the fluid in the coelom is 
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done using channels between segments of the worm.  Each segment 
possesses nephridia and a pore allowing draining of fluid into the environment 
(12).  Since this pore to the environment exists, the coelom is not aseptic and 
always has bacteria, protozoans, and fungi, however the worm has ways to keep 
these populations in check (242).  One study reports that the coelomic fluid of 
earthworms contains 6 x 105 bacteria/mL, with the number of suspected 
phagocytic cells being ten times higher in concentration (243).  The combination 
of these phagocytic coelomic cells and humoral compounds keeps microbial 
populations at tolerable levels (12).   
The investigation into the compounds present in the coelomic fluid of 
earthworms has led to the isolation of more than 40 proteins, that show cytolytic, 
proteolytic, antimicrobial, hemolytic, hemagglutinating, tumorolytic, and mitogenic 
activities (8-11).  The majority of hemolytic proteins in Eisenia fetida species 
show either bactericidal and/or bacteriostatic activity against numerous 
pathogenic soil bacteria including Aeromonas hydrophila and Bacillus 
megaterium, which are suspected earthworm pathogens (10,244-246).  Some of 
the proteins with antibacterial activity in the coelomic fluid are called Eisenia 
fetida andrei factors or EFAFs, two specific glycoproteins secreted by 
chloragocytes and eleocytes (244,247,248).  These show antibacterial activity 
against both Gram-positive and Gram-negative bacteria (10,249,250).  These 
have a particularly strong activity against bacteria pathogenic to the earthworm 
(245,246,251).  These EFAFs have now been characterized more specifically 
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and named fetidins, one of these proteins with a corresponding DNA sequence 
40 kDa length was cloned and found that its amino acid sequence has an N-
glycosylation site and a peroxidase component (252,253).  Another hemolytic 
protein type with a length of 41 kDa that was identified independently was termed 
a lysenin (254).  Three discovered lysenin-related proteins were found to have 
high sequence homology with fetidins (255).  These proteins bind sphingomyelin 
in the target cell membrane and create 3 nm pores (256,257).  However, lysenin 
acts on bacteria differently, since their membranes lack sphingomyelin (255).    
Another of these substances is a bacteriolytic lysozyme, which breaks 
down 1,4-β-D linkages between N-acetylmuramic acid and N-acetyl-D-
glucosamine in peptidoglycan of bacterial cell walls.  This helps to protect the 
worm against bacterial infections, particularly those caused by Gram-positive 
bacteria.  Lysozyme effects are seen in extracts from both coelomocytes and 
coelomic fluid extracts (258).  Earthworm lysozyme has both lysozyme and 
isopeptidase activities and is upregulated after a challenge with either Gram-
positive or Gram-negative bacteria (12).  
Coelomic cytolytic factor (CCF) is a protein with known cytolytic activity 
against invading bacteria; it is also a pattern recognition molecule (259). Pattern-
recognition molecules bind microbial pathogen-associated molecular patterns 
(PAMPs).  The PAMP recognized by CCF is the O-antigen of LPS of Gram-
negative bacteria and muramyl dipeptide and muramic acid of peptidoglycan of 
Gram-positive bacteria as well as β-1,3-glucanase and N,N’-diacetylchitobiose of 
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yeast. (260-262).  The mRNA for CCF is also upregulated upon microbial 
stimulation (263).  This molecule activates a prophenoloxidase cascade, causing 
cytotoxic and antimicrobial compounds to form (264).  CCF has two lectin-like 
domains; one has homology with the polysaccharide and glucanase motifs of β-
1,3-glucanases and is located in the central part of the CCF.  The C-terminal 
tryptophan-rich domain interacts with N,N’-diacetylchitobiose, muramyl dipeptide, 
and muramic acid (262).  Despite homology with β-1,3-glucanases, this CCF 
doesn’t show the same enzymatic ability (265-267). This compound is a 
contributor to cell-mediated cytotoxic reactions and can be secreted by 
phagocytic coelomocytes once stimulated by lipopolysaccharide (268).  It has 
also been demonstrated that CCF agglutinates Gram-positive and Gram-negative 
bacteria (260).  CCF and Tumor necrosis factor (TNF) also show some similarity.   
However, anti-TNF antibodies don’t inhibit CCF indicating that different 
mechanisms of action for lysis must exist between the two molecules (12).   
Once bacteria have been disabled, they can be removed from the coelom 
in several ways including: excretion through the nephridia, engulfment by cells in 
the nephrostome or ampulla of the nephridia, phagocytosis by specific 
coelomocytes and phagocytic cells (nonfunctional cells can then be excreted), 
and encapsulation large foreign bodies including agglutinated bacteria or 
parasites (11,269-271).  In encapsulation, the process begins with recognition of 
foreign material; this is then surrounded by coelomocytes, which form a capsule 
also called a brown body around the material.  When capsule then reaches a size 
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of 1-2 mm wide, external cells lose adhesion with the epithelium such that the 
capsule migrates toward the posterior segments to be eliminated (272-275).  In 
E. fetida, most typical brown bodies have wastes, agglutinated bacteria, 
gregarines, or nematodes (11).   
 The coelomocytes present in the coelomic fluid are typically identified via 
morphological and cytochemical differences (276,277).  There are three main 
types of coelomocytes: eleocytes and hyaline or granular amoebocytes.  
Eleocytes or chloragogen cells have nutritive and accessory functions (278).  
These include the collection of contaminants and other stray particulate in the 
coelom and the also release some antimicrobial substances (12).  Eleocytes also 
have an identifiable collection of vesicles in their cytoplasm called chloragosomes 
(279).  Amoebocytes have immune functions including phagocytosis and cytokine 
production (12).  Granular amoebocytes tend to have increased phagocytic 
activity over hyaline amoebocytes (276).  The materials these phagocytes engulf 
include inert particles, bacterial cell wall pieces, and foreign cells (269).  
Phagocytosis by coelomocytes can be modified by humoral components as well 
as opsonins, which coat the particle to enhance the process (280).  In one 
experiment, the phagocytic activity of coelomocytes was improved in the 
presence of mammalian opsonins, IgG, and C3b (281).  It has been observed 
that the coelomic cells of Dendrobaena veneta show an increased phagocytosis 
of known earthworm pathogens (Bacillus megaterium and Aeromonas 
hydrophila) over non-pathogenic species, indicating specific recognition by the 
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phagocytes (15).  There is also evidence that EFAFs and CCF may have roles 
in opsonization (259,282).   
A Brief Restatement of Hypothesis and Methods 
This study sought to determine whether or not the symbiotic bacteria of 
Eisenia fetida have a role in immune-mediated defense against Mycobacterium 
smegmatis.  Thus, the hypothesis for this study is: the coelomic cells and fluid of 
the earthworm E. fetida have antimycobacterial properties, which may be 
influenced by the presence of V. eiseniae or other symbionts.  In order to 
examine the immune activity of the coelomic fluid of this worm against M. 
smegmatis strain mc2155, the viability of mc2155 after treatment was studied.  
Phagocytic interactions between coelomic cells and mc2155 bacteria were 
observed with microscopy.  The coelomic fluid and cells of both symbiont-positive 
and symbiont-negative earthworms were assessed.   
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3. Materials and Methods 
Worm Populations 
An earthworm colony (originally purchased from Carolina Biological) has been 
maintained for several years at Minnesota State University, Mankato.  For this 
study, worms were routinely maintained on either a sphagnum moss or cellulose 
bedding and fed a commercial worm food (Magic Worm Food, Magic Products, 
WI).  Bedding was replaced as needed and feeding occurred weekly.  
Elimination of the Symbiont 
Elimination of symbionts required sequential treatments with antibiotics.  Control 
worms (symbiont (+)) were treated in the same manner without antibiotics.  For 
each treatment 1:100 dilution of an antibiotic mix (10,000 units/mL of penicillin, 
10 mg/mL of streptomycin, and 25 µg/mL of amphotericin B (Sigma; #A5995)) 
was prepared.  A maximum of 11 worms were exposed in 10mL of antibiotics in 4 
oz. glass jars per treatment period.  The control worms were treated with 
deionized water. Twenty-four seven-month-old Eisenia fetida earthworms were 
cleaned to remove any bedding or slime on their body prior to placement in 
antibiotics or water.  These worms remained in jars with 20 mL of deionized 
water, a 2 cm2 piece of paper towel and 3-5 mg of Magic Worm Food until the 
next treatment. The antibiotic treatment was repeated 24, 48, and 72 hours after 
the initial treatment.  The antibiotic-treated and control worms were then placed 
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in an 8 oz. plastic container along with moistened bedding.  The container had 
a perforated lid for airflow.  These were kept at room temperature in the dark. 
Development of a symbiont free colony 
The treated worms were given food once a week and any cocoons produced by 
the worms were counted and placed in jars.  Any hatched worms were also 
counted and placed in 8 oz. plastic containers.  These worms were kept separate 
by symbiont status and generation and were fed and checked for adult worms 
weekly.  Once adult worms were discovered they were placed in a larger 12 oz. 
plastic container.  This allowed for breeding of symbiont free populations.  The 
generation after the antibiotic treatment was used in the experiments as symbiont 
(-) worms.  All containers were kept in the dark at room temperature.   
Confirmation of Symbiont Status 
Cocoons from symbiont positive and negative worms were observed under a 
dissecting microscope. Tested cocoons from each population had embryos that 
hadn’t yet formed elongated worms and appeared to either have 4 eggs or be at 
a 4-cell stage.  The cocoons were washed and their contents were squeezed out 
into a microfuge tube using forceps.  The cocoon contents were suspended in 50 
µL of 4% paraformaldehyde (50mM phosphate buffer, pH 7.4, 0.15M NaCl).   The 
tube was then incubated at room temperature for 2 hours.  The microfuge tube 
was centrifuged at 8 for 10 minutes (Mini-Centrifuge, Bel-Art Products, NJ), the 
supernatant was poured off and the pellet resuspended in 1mL of phosphate 
buffered saline (PBS); it was centrifuged at speed 8 for another 10 minutes.  The 
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supernatant was poured off and the PBS wash step was repeated.  Then the 
pellet was suspended in 50 µL of warmed hybridization buffer [(0.9 M NaCl, 0.02 
M Tris-HCl pH 8, 30% formamide, 0.01% SDS) (Sigma-Aldrich; F9037), distilled 
water, and 10% SDS with 10 µL of Verminephrobacter-specific probe, LSB 145 
(S-G-Acidov-0145-a-A-18)] were added and the tube was incubated at 47°C for 2 
hours.  The tube was then centrifuged for 10 minutes at speed 8 and the 
supernatant was removed.  The pellet was suspended in 1mL of warmed wash 
buffer (0.1 M NaCl, 0.02 M Tris-HCl, pH 8, 0.005M EDTA, distilled water, and 
0.01% SDS) then incubated at 47°C for 20 minutes.  The tube was then 
centrifuged at speed 10 for 2 minutes to quickly pellet the cells, the supernatant 
was poured off and the remaining pellet was suspended via pipetting.  The 
suspension was then pipetted on a slide, and a coverslip was sealed in place 
with clear nail polish added along the edges.  This slide was then observed using 
a fluorescence microscope with TRITC and DAPI filters for the probe and the 
worm tissue fluorescence, respectively.  The symbiont fluoresced orange and the 
symbiont-negative cocoon was confirmed as free of any fluorescence.  The 
symbiont positive cocoon was confirmed as having orange fluorescing bacteria.   
Coelomic Cell Harvest 
For each experiment four worms from control and treatment populations were 
selected for coelomic cell harvest.  These worms were cleaned in deionized 
water and massaged to induce defecation.  The worms were then transferred to a 
sterile Petri dish containing 5mL of phosphate buffered saline (PBS).  Each worm 
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was then exposed to electric shock for 10 seconds using electrodes attached 
to a 9-volt battery.  The worms were then left in the dish for 10 minutes to allow 
for coelomic fluid extrusion.  The worms were then stripped of any mucus fluid, 
containing cells, that covers their body and they were returned to their bedding to 
recover for future procedures.  The PBS and mucus fluid was then transferred to 
a sterile tube.  Five milliliters of PBS were then added to the plate to collect any 
additional mucus fluid remaining and added to the tube.  This tube was then 
centrifuged for 10 minutes at 1000 rpm (200 x g).  The supernatant fluid was 
passed through a 0.45µm filter into a sterile tube; this was used for the filtered 
extract treatment.  The pellet was resuspended with 2.5mL of PBS and 20µL of 
the fluid were added to a hemacytometer.  This suspension was examined under 
the microscope and all coelomic cells were counted in five 0.1 mm3 grids.  The 
number of cells per 0.1 mm3 was used to calculate coelomic cell concentration.  
The remaining suspension was used for coelomic cell association trial.   
mc2155 Maintenance and Dilution 
A frozen stock culture of Mycobacterium smegmatis strain mc2155 provided by 
Dr. Timothy Secott was used to inoculate 9mL of tryptic soy broth (TSB)(BBL).  
This culture was grown at 37°C for 3 days and was used as the source of weekly 
cultures used for the experiment.  Several days prior to an experimental trial, a 
loopful of the TSB culture was added to 9 mL TSB containing 5 µL of Tween 80 
and incubated for 3 days at 37°C.  The culture was measured for turbidity using a 
Spec 20 spectrophotometer (Bausch and Lomb) set at 600nm.  The culture was 
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then diluted using 1% peptone blanks to optical densities of 1x10-4, 5x10-5, 
2.5x10-5, and 1.25x10-5.  
Coelomic Fluid Extract Treatment of mc2155 
In microfuge tubes, 200 µL of PBS were added to either 200µL of the symbiont 
positive or negative extracts for extract controls.  Also, 200µL of the different M. 
smegmatis dilutions and 200 µL of PBS were added to tubes for mycobacterial 
controls.  Aliquots of 200µL of symbiont-positive or -negative extracts were added 
to the M. smegmatis dilutions for the experimental trials.  After a 30-minute 
incubation at room temperature, 100µL of each solution was spread-plated on of 
tryptic soy agar (TSA).  These plates were then incubated at 37°C for 3 days.  
The plates were then counted for M. smegmatis colonies and any colony merging 
or contaminants were noted.   
Coelomic Cell Association Treatment 
Using a concentration of mc2155 determined by spectrophotometer (between 
0.140 and 0.980 across the trials), the culture was diluted in three 1:10 dilutions 
in 1% peptone.  A volume of 200µL of each dilution and the undiluted bacteria 
was mixed separately with 200µL of coelomic cells harvested from symbiont (+) 
and symbiont (-) worms.  The coelomic cells alone and the mycobacteria alone 
were added to 200µL of PBS as control treatments.  These tubes were then 
allowed to incubate at room temperature for 30 minutes.  After incubation, the 
tubes were centrifuged at speed 5 for 10 minutes (Bel-Art Mini centrifuge) and 
the supernatant was poured out.  The pellet was then suspended using the 
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remaining liquid and approximately 100µL were smeared onto each slide and 
allowed to dry.  The smears were then Gram stained.  These slides were then 
observed at 1000x magnification and 300 total coelomic cells were counted as 
either adhered with or not adhered with mycobacteria.  If any slides had too high 
of a mycobacterial concentration causing nearly all coelomic cells to appear as 
having adherent mycobacteria they were not used for the count or the study.  
This was also true if a slide had less than 300 coelomic cells.  The coelomic cells 
without mycobacteria were used as a control to ensure there were no 
contaminant bacteria giving false positives for the experimental bacteria.   
Statistical Analysis 
To determine differences between the symbiont (+) and (-) populations as well as 
between the untreated mycobacteria, statistical analyses were performed in 
SPSS.  For the coelomic association trials, a univariate analysis was performed 
to determine differences in percent association at the different dilutions.  
Individual differences were determined by a Tukey HSD or by Games Howell in 
the case of nonhomogeneous variances determined by a Levene’s Test.  
Univariate analyses were also performed on the variables associated with the 
cell-free coelomic extract treatments of mc2155.  These were also tested for 
homogeneity of variances with the Levene’s test and individual significant 
differences assessed by the Tukey HSD test or Games-Howell test for 
nonhomogeneous data.  To determine differences among the survival 
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percentages for symbiont (+), symbiont (-), and mycobacterium alone 
populations, univariate analysis was performed.   
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4. Results 
The antimycobacterial activity of soluble compounds and coelomic cells in 
the coelomic fluid of symbiont (+) and (-) E. fetida earthworms were assessed in 
this project.  
Adherence 
The number of cells with mycobacteria adhered to their surface was 
divided by the total cells (300) counted to obtain the percent association; three 
concentrations of mc2155 bacteria were used.  As the concentration decreased, 
so did adherence (Fig. 1).  Differences exist between the percent associations 
corresponding to the varying dilutions when p=0.01 was used as the level for 
significance, but not by symbiont status (+) or (-) at each dilution (p= 0.663).  All 
individual probabilities are displayed in Appendix A.   
 
 
Figure 1-Percent Association by Dilution-Significant differences exist between 
the different dilutions, but not by symbiont status. 
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Antimycobacterial Activity 
To determine if the coelomic fluid had antimycobacterial activity, the fluid 
was mixed with different concentrations of mc2155 cells, incubated, and aliquots 
of the mixes spread-plated for viable bacterial counts.  Using a 72-hour culture, 
dilutions with PBS were made to 1x10-4, 5x10-5, 2.5x10-5, and 1.25x10-5 OD.  Two 
dilutions were used per trial. 
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Table 1-The Effect of Coelomic Fluid Treatment on Mycobacterium 
smegmatis mc2155 Concentration Viability 
 
Trial Number Concentration 
of mc2155 
(OD600) 
Symbiont (+) 
Average  
CFU/mL 
mc2155 
Symbiont (-) 
Average 
CFU/mL 
mc2155 
Mycobacterium 
Alone 
Average 
CFU/mL mc2155 
1 1.00x10-4 TMTC TMTC 1.90x107 
5.00x10-5 2.60x107 4.14x107 4.46x107 
2 1.00x10-4 1.73x107 1.34x107 1.17x107 
5.00x10-5 2.14x107 2.24x107 2.08x107 
3 
1.00x10-4 8.50x106 1.05x107 1.42x107 
5.00x10-5 2.10x107 2.40x107 1.88x107 
4 1.00x10-4 1.46x107 1.93x107 TMTC 
5.00x10-5 2.76x107 3.02x107 2.86x107 
5 5.00x10-5 3.48x107 3.18x107 2.98x107 
2.50x10-5 8.16x107 6.08x107 4.69x107 
6 2.50x10-5 2.60x107 3.80x107 1.52 x107 
1.25x10-5 3.92x107 3.84x107 7.28 x107 
7 2.50x10-5 3.60x107 3.28x107 TMTC 
1.25x10-5 4.16x107 3.12x107 TMTC 
No treatment type was significantly different than the others.  TMTC: Too Many 
Colonies to Count (> 300). 
Overall, when mc2155 bacteria were treated with the fluid, no difference in 
surviving bacteria occurred by source of the coelomic fluid (symbiont (+) or (-)) 
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nor did the coelomic fluid-treated bacterial concentrations differ from the 
untreated mycobacteria (Table 1).      
ANOVA of the different trials indicated a significant difference (p= 0.001) 
among the trials of surviving bacteria.  Post hoc tests indicated differences 
between trials 2 and 5 (p= 0.004), 2 and 6 (p= 0.033), 3 and 5 (p= 0.002), and 3 
and 6 (p= 0.019).  These correspond to differences due to the concentration of 
bacteria added.   
 
 
Figure 2a- The Effect of Coelomic Extract Treatment on Higher 
Concentrations of Mycobacterium smegmatis mc2155- The diluted 
concentration of mc2155 in trials 1-4 are compared amongst the different 
treatments for the lower concentration dilutions.  Trial 5 was excluded from the 
figure due to results falling between the high and low concentration groups.   
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Figure 2b- The Effect of Coelomic Extract Treatment on Lower 
Concentration Mycobacterium smegmatis mc2155-The diluted concentration 
of mc2155 in trials 6 and 7 is compared amongst the different treatments for the 
lower concentration dilutions.  As bacterial concentration in OD increased, viable 
concentration decreased.  
 
ANOVA revealed a significant difference between the surviving 
mycobacteria by the different dilutions (p <0.001).  This difference was found 
using the Welch test, as there was a lack of homogeneity of variance (p= 0.006).  
The individual differences were found via a Games-Howell test also due to the 
lack of homogeneity of variance.  The only significant difference was between the 
1x10-4 and 5x10-5 dilutions (p<0.0001). 
Mycobacterium smegmatis mc2155 produced a higher bacterial 
concentration at lower absorbance dilutions than at lower concentration dilutions 
(Table 1, Figs. 2a & 2b).  However, despite significant increases in initial 
concentration, no significant differences existed between the two coelomic fluid 
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treated bacteria.  The only significant differences found were between some of 
the different initial concentrations within each coelomic fluid treatment 
(Appendices B-D) and some at the differences between the coelomic fluid 
treatments (Appendices E-G).   
Table 2-Average Pooled Percent Survival by Treatment- Differences in 
percent survival occurred by dilution but not by treatment (symbiont (+) or (-)). 
Initial Concentration of 
mc2155 (OD600) 
Symbiont (+) Coelomic 
Fluid Mean Percent 
Survival ± SD 
Symbiont (-) Coelomic 
Fluid Mean Percent 
Survival ± SD 
1x10-4 89.98 ± 30.12 96.21± 29.96 
5x10-5 91.72 ± 19.68 105.05 ± 26.41 
2.5x10-5 186.01± 115.18 170.47± 57.87 
1.25x10-5* 55.49 ± 2.33 47.80 ± 6.99 
*-Only one set of untreated controls yielded countable plates 
The percent survival statistic was calculated using the average 
concentration of untreated mycobacteria as 100%.  The bacterial concentration 
from each dilution was used to calculate the percentage (Table 2).  Significant 
differences occurred by dilution (p=0.004) but not by population (p=0.963).  No 
interaction was observed between dilutions and treatment populations  
(p=0.940).  All individual differences are noted in Appendices H-J.   
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Figure 3-Mycobacterium smegmatis mc2155 Concentration After Treatment 
with Coelomic Cell Extract by Coelomic Cell Concentration and Treatment 
Group- The symbiont (+) and (-) treatments seem to stratify with a bit of overlap 
with the symbiont (-) garnering more coelomic cells.  However, there is no 
significant difference between the coelomic cell concentrations or treatment 
types.    
 
Coelomic cell concentration varied from trial to trial, however coelomic cell 
concentration didn’t correspond to an increase or decrease in mc2155 
concentration by cluster (Fig. 3).  A correlation of 0.165 existed (r2=0.027) 
between coelomic cell concentration and surviving mycobacteria, but this was not 
found to be significant (p= 0.421). 
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Variability in Bacterial Cultures and Coelomic Cell 
Concentration 
Figure 4- Mycobacterium smegmatis mc2155 Concentration by Absorbance 
of Starting Culture-There were increasing plate counts with increasing 
absorbance, dropping off at 0.696.  No significant differences were detected 
overall. 
Quantified bacterial concentrations exhibited great variability in the 72-
hour cultures of mc2155 used in these experiments.  Generally speaking as the 
absorbance of the culture increased there was a resulting increase in plate count.  
However, an examination of the starting culture absorbance values (Fig. 4) 
revealed no significant difference between plate counts (p= 0.066) at the different 
measured absorbance values for a 72-hour culture.  Due to a lack of 
homogeneity of variances, a Welch test and a Games-Howell post-hoc test was 
also performed.  This did reveal a difference (p= 0.037) in bacterial concentration 
between the starting absorbance values of 0.165 and 0.484.   
The viable counts increased when the bacteria were diluted (Fig. 5).  No 
significant differences in concentrations were found between the different 
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dilutions (p=0.055).  This was found using a Kruskal-Wallis test, which was 
necessary due to a lack of normality of the 1.25 x 10-5 dilution.   
 
 
Figure 5-Average Colony Counts of Untreated Mycobacterium smegmatis 
mc2155 by Dilution-As the absorbance increased bacterial concentration 
decreased, however no significant differences were found.  Only one sample of 
the 1.25x10-5 dilution was viable so no standard deviation was calculated. 
 
An examination of the mycobacterial concentration in relation to coelomic 
cell concentration revealed a clustering of coelomic cell concentration by 
population (Fig. 3).  A comparison of the coelomic cell concentrations (Figures 3 
& 6) between the symbiont (+) and (-) shows a significant difference (p= 0.001).  
This difference shows an increased mean coelomic cell concentration in the 
symbiont (-) population of 4.46 x 105 coelomic cells/mL over the symbiont (+) 
population of 2.70 x 105 coelomic cells/mL.   
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Figure 6- Variable Coelomic Cell Concentration by Trial and Worm 
Population-Coelomic cell counts are the compilation from four earthworms’ 
ceolomic exudates.   
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5. Discussion 
Adherence of Coelomic Cells with Mycobacteria 
This project sought to elucidate any possible antimycobacterial activity 
present in the earthworm Eisenia fetida and whether a previous disruption of 
normal microbiota would affect this activity.  The first system used coelomic cells 
extracted from symbiont (+) and (-) earthworms and three dilutions of 
Mycobacterium smegmatis mc2155 bacteria.  It was found that the percentage of 
coelomic cells with associated mycobacteria was not significantly different in the 
worm populations after disruption of the earthworm microflora.  This indicates 
that the nephridial symbionts had no effect on the coelomic cell binding of 
mc2155 cells.  
Furthermore, as the bacterial concentration in the mixtures decreased, the 
percentage of coelomic cells with adhered bacteria also decreased, however this 
decrease in percentage adhered was not proportional to the 10-fold decrease in 
concentration.  The high association observed may have been due to the higher 
number of bacteria remaining after the wash step.  The remaining unbound 
bacteria may have associated with coelomic cells once they were placed on 
slides.  The lower two concentrations of bacteria used differed in percent 
adherence by 50%.  Thus, it appears as though either a low proportion of 
coelomic cells can bind M. smegmatis or the binding requires an increased 
incubation time or different conditions for adherence.  If phagocytes specifically 
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recognized mycobacteria, similar binding proportions would be seen across at 
least two of the dilutions.  The higher concentrations of bacteria were not useful 
for determining coelomic cell association, due to the sheer numbers of bacteria 
on the slide.  
There may be other considerations to take into effect with the 
experimental design including the use of PBS in the experiment.  There was 
passive adherence of the bacteria to the coelomic cells in this solution, but 
without an energy source the coelomic cells may be unable to bind tightly to the 
bacteria.  It is possible that a longer incubation time may be necessary for proper 
recognition and adherence of the mycobacteria and a nutrient source may be 
necessary for that longer incubation.  However, an incubation time longer than 3-
4 hours may allow M. smegmatis to replicate, affecting bacterial concentration in 
solution (173).  Thus, the bacteria may have to be inactivated or a slower growing 
species like MAP may have to be used.   
Assessment of Coelomic Fluid for Antimycobacterial Activity  
The assessment of antimycobacterial activity by reductions in viable plate 
counts was plagued with issues related to inconsistent growth by the bacteria.  
However, cell-free coelomic-cell extracts from symbiont (+) and (-) worms 
resulted in no significant difference in the concentrations of surviving bacteria.  
Two compounding problems arose with this method.  There is a certain amount 
of variation in coelomic cell concentrations from trial to trial, as well as differences 
in bacterial plate counts.  If there was variability related to the coelomic cell 
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concentration prior to filtration of the fluid, it was not significant.  Also even 
though the coelomic cell concentration varied from trial to trial, no resulting 
significant difference in plate count was observed.  
Compared to common model bacteria such as E. coli that are easier to 
manipulate, Mycobacterium smegmatis culture presents difficulties.  Firstly, this 
bacterium grows slower than some common model bacteria, taking 2-3 days to 
grow colonies or a turbid culture.  However, M. smegmatis is preferable to other 
strains of mycobacteria that take weeks to months to grow.  Also, this bacterium 
grows in clumps; in broth culture it tends to form a flaky mat on the surface of the 
liquid and on agar plates the bacteria form spreading colonies.  To aid dispersal 
of bacteria, the surfactant Tween 80 was added to the culture medium.  However, 
inconsistencies in the dilutions still occurred.  However, more dilute starting 
concentrations yielded more countable plates.  A related issue is also the 
fluctuations in the absorbance of the starting cultures for each trial.  The mid-log 
phase for M. smegmatis (at 600nm) is 0.5 OD and most of the cultures fell near 
that absorbance (283).  However, if the bacteria aren’t fully in solution, the OD 
may be inaccurate and the dilution may be too high or low as a result.   
Despite the variability of bacterial cultures, no evidence of 
mycobactericidal activity in the cell free coelomic fluid was found.  Since the 
concentration of coelomic cells used to make the extracts also varied with each 
trial, they added to possible inconsistency in results.  While coelomic cell 
concentration differed by trial overall, the symbiont (-) population yielded a 
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significantly higher coelomic cell concentration than the symbiont (+) 
population.  How these differences in coelomic yield relate to the loss of bacterial 
symbionts remains unclear.  Coelomic cells function in the innate immune 
defenses of the earthworm (12).  It may be a compensatory increase in immune 
cells to act on bacteria that have taken up residence in areas normally occupied 
by symbiotic bacterial flora.  Thus, the increase in coelomic cell production may 
be a result of a persistent inflammatory reaction in response to disrupted 
bacterial populations in the worm.  Conversely, the increase in coelomic cell 
concentration may indicate the microflora of the worm may be essential to the 
regulation of innate response.  Another possibility is that the symbiont’s presence 
during development helps to acclimatize the cells’ immune response.   
This project has assessed the coelomic fluid and coelomic cells of E. 
fetida earthworms for antimycobacterial activity.  By the parameters of this 
project, there has been no obvious activity against M. smegmatis.  An 
assessment of Lumbricus terrestris earthworms in MAP-infested soil suggested 
resistance to mycobacteria, as few worms in that environment had detectable 
MAP in their gut (40).  If that kind of antimycobacterial activity also exists in E. 
fetida, it likely isn’t occurring via phagocytic recognition or antimycobacterial 
substances in the coelomic fluid.  MAP may be recognized differently by L. 
terrestris than M. smegmatis by E. fetida.  A survey of tissue samples and 
coelomic cells of the both earthworm guts for mycobacteria in both of these 
instances might be useful to elucidate the method of elimination.   
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The null hypothesis that E. fetida coelomic cells and fluid exhibit no 
antimycobacterial properties was upheld in this instance.  Disruption of symbiotic 
bacteria in this earthworm had no direct effect on phagocytic activity of the 
coelomic cells or bactericidal/bacteriostatic properties of the coelomic fluid.  
Under the conditions of these experiments, treatment of mycobacteria with 
coelomic fluid showed no apparent negative effect on mycobacterial growth 
compared to the untreated mycobacteria after treatment, as there was no 
significant reduction in viability in either of the treated populations.  The data 
demonstrated that no antimycobacterial activity against M. smegmatis could be 
observed. 
There are some variations on methodology that one could explore in future 
research.  This research only used 4 worms for coelomic cell harvest; higher 
concentrations of coelomic cells may have yielded detectible activity.  This would 
necessitate additional worms per harvest.  If additional worms were used, a more 
concentrated fluid of any antimicrobial substances could possibly show more 
obvious results and gradations down to a minimum inhibitory/bactericidal 
concentration could be found.   
Another area to investigate would be the potential injury suffered by the 
mycobacteria after coelomic fluid treatment.  The bacteria may be damaged in 
some way that is not readily apparent by plate count.  If working with more 
concentrated coelomic fluid than used in this study in combination with 
visualization, perhaps by using electron microscopy, one might be able to see 
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changes in the cell wall structure or atypical cell shape as a result of treatment.  
This was a method used previously to observe the damage of another earthworm 
derived antimycobacterial substance (7).  Alternatively, injury may make the 
bacteria more susceptible to a second assault that could result in death.  This 
research used only M. smegmatis.  Since there has been noted antimicrobial 
activity in coelomic fluid previously, it is possible that these worms may have 
activity against another bacterium of interest such as certain troublesome Gram 
(-) bacteria (4,249,250,284).  Another possibility is that an injury might progress 
to a fatal injury after a longer incubation period was used prior to plating. 
The most intriguing data from this project are the coelomic cell 
concentration differences between symbiont (+) and (-) earthworms.  A larger 
survey of these earthworm populations, either with more worms per harvest or 
more harvests overall, would be beneficial to see if this is a consistent trend in 
regards to symbiont status or if this was only in relation to the two separate 
breeding populations used in this study.  Since the aim of the study didn’t directly 
address coelomic cell concentrations, the data are unfortunately limited in this 
area.  However, resident microflora do exert an antimycobacterial influence in 
another earthworm species (7).  Thus, disruption of the microbiota of the worms 
used in the study may exhibit different susceptibilities to earthworm pathogens.   
The increased concentration of coelomic cells in the disrupted worms 
indicates that there is a need for more immune cells than in untreated worms.  
The loss of Verminephrobacter eiseniae cannot be determined as the cause of 
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the increase in coelomic cells, as other bacteria were likely eliminated from the 
worms when they were treated with antibiotics.  Only V. eiseniae was assayed as 
it is a well-described symbiont of the worm and the loss of this symbiont indicated 
a disrupted microbiota.   
This experiment focused on the phagocytic coelomocytes or amoebocytes 
but also indirectly investigated the production of antimicrobial substances by 
eleocytes (12).  It appears as though no phagocytic recognition occurred, based 
on the data collected in this experiment.  However, it is possible that an 
antimycobacterial substance produced by eleocytes in the coelomic fluid may 
have been present, but at too low a level to show a noticeable effect on mc2155 
plate counts.   
Conclusion 
In closing, this project investigated the effects of disrupting the bacterial 
flora and symbionts from E. fetida on potential antimycobacterial defenses.  No 
significant trends with regard to phagocytic activity or direct antimycobacterial 
activity were observed.  While some aspects of this study could be modified to 
further examine these trends possibly using more concentrated extracts, this 
would appear to be an unproductive area to pursue.  The most likely area of 
interest would be the effect of symbiont removal on the coelomic cell populations.  
A closer examination of the earthworm’s physiological response to the antibiotic 
treatment may elucidate the source of the coelomic cell concentration 
discrepancy.  
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Appendices 
 
Appendix A-Probability Values of Average Mycobacterial Concentration 
Between All Dilutions for Both Symbiont (+) and (-) Treated Mycobacteria 
Dilution 
and 
Treatment 
p-value 
against 
1x10-3 
Symbiont 
(+) 
p-value 
against 
1x10-3 
Symbiont 
(-) 
p-value 
against 
1x10-2 
Symbiont 
(+) 
p-value 
against 
1x10-2 
Symbiont 
(-) 
p-value 
against 
1x10-1 
Symbiont 
(+) 
p-value 
against 
1x10-1 
Symbiont 
(-) 
1x10-3 
Symbiont 
(+) 
----- 0.793 0.032 0.001 <0.0001 <0.0001 
1x10-3 
Symbiont 
(-) 
0.793 ----- 0.012 0.002 <0.0001 <0.0001 
1x10-2 
Symbiont 
(+) 
0.032 0.012 ----- 0.534 0.003 <0.0001 
1x10-2 
Symbiont 
(-) 
0.001 0.002 0.534 ----- .535 <0.0001 
1x10-1 
Symbiont 
(+) 
<0.0001 <0.0001 0.003 .535 ----- 0.636 
1x10-1 
Symbiont 
(-) 
<0.0001 <0.0001 <0.0001 <0.0001 0.636 ----- 
Tukey HSD testing was used to determine p-values; in cases of inequality of 
variances the Games-Howell test was used.   
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Appendix B-Probability Values of Untreated Mycobacteria Average 
Mycobacterial Concentration Between Different Dilutions 
Dilution and 
Treatment 
1.00x10-4 
Mycobacteriu
m Alone 
5.00x10-5 
Mycobacteriu
m Alone 
2.50x10-5 
Mycobacteriu
m Alone 
1.25x10-5 
Mycobacteriu
m Alone 
1.00x10-4 
Mycobacteriu
m Alone 
--- 0.390 0.648 0.001 
5.00x10-5 
Mycobacteriu
m Alone 
0.390 --- 0.985 0.005 
2.50x10-5 
Mycobacteriu
m Alone 
0.648 0.985 --- 0.005 
1.25x10-5 
Mycobacteriu
m Alone 
0.001 0.005 0.005 --- 
All p-values were found by Tukey HSD testing. 
 
Appendix C-Probability Values of Symbiont (+) Coelomic Fluid Treated 
Average Mycobacterial Concentration Between Different Dilutions 
Dilution and 
Treatment 
1x10-4 
Symbiont (+) 
5x10-5 
Symbiont (+) 
2.5x10-5 
Symbiont (+) 
1.25x10-5 
Symbiont (+) 
1.00x10-4 
Symbiont (+) --- 0.057 0.403 0.011 
5.00x10-5 
Symbiont (+) 0.057 --- 0.657 0.014 
2.50x10-5 
Symbiont (+) 0.403 0.657 --- 0.967 
1.25x10-5 
Symbiont (+) 0.011 0.014 0.967 --- 
Differences were found by Games-Howell (lack of heterogeneity of variances 
p=0.005) 
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Appendix D- Probability Values of Symbiont (-) Coelomic Fluid Treated 
Average Mycobacterial Concentration Between Different Dilutions 
Dilution and 
Treatment 
1.00x10-4 
Symbiont (-) 
5.00x10-5 
Symbiont (-) 
2.50x10-5 
Symbiont (-) 
1.25x10-5 
Symbiont (-) 
1.00x10-4 
Symbiont (-) --- 0.156 0.014 0.132 
5.00x10-5 
Symbiont (-) 0.156 --- 0.223 0.917 
2.50x10-5 
Symbiont (-) 0.014 0.223 --- 0.700 
1.25x10-5 
Symbiont (-) 0.132 0.917 0.700 --- 
All p-values were found by Tukey HSD testing. 
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Appendix E-Probability Values of Untreated Mycobacteria Against 
Coelomic Fluid Treated Average Mycobacterial Concentration Between 
Different Dilutions 
Dilution and 
Treatment 
1.00x10-4 
Mycobacterium 
Alone 
5.00x10-5 
Mycobacterium 
Alone 
2.50x10-5 
Mycobacterium 
Alone 
1.00x10-4 
Symbiont (+) 0.680 0.049 0.365 
5.00x10-5 
Symbiont (+) 0.011 0.478 0.885 
2.50x10-5 
Symbiont (+) 0.025 0.688 0.677 
1.25x10-5 
Symbiont (+) 0.002 0.080 0.298 
1.00x10-4 
Symbiont (-) 0.874 0.060 0.355 
5.00x10-5 
Symbiont (-) 0.035 0.847 0.698 
2.50x10-5 
Symbiont (-) 0.002 0.353 0.419 
1.25x10-5 
Symbiont (-) 0.002 0.495 0.560 
The untreated mycobacteria didn’t have countable plates at the 1.25x10-5 dilution 
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Appendix F- Probability Values of Symbiont (+) Coelomic Fluid Treated 
Average Mycobacterial Concentration Against Symbiont (-) Coelomic Fluid 
Treated and Untreated Average Mycobacterial Concentration at Between 
Different Dilutions 
Dilution and 
Treatment 
1.00x10-4 
Symbiont (+) 
5.00x10-5 
Symbiont (+) 
2.50x10-5 
Symbiont (+) 
1.25x10-5 
Symbiont (+) 
1.00x10-4 
Mycobacterium 
Alone 
0.680 0.011 0.025 0.002 
5.00x10-5 
Mycobacterium 
Alone 
0.049 0.478 0.688 0.080 
2.50x10-5 
Mycobacterium 
Alone 
0.365 0.885 0.677 0.298 
1.00x10-4 
Symbiont (-) 0.812 0.013 0.026 0.004 
5.00x10-5 
Symbiont (-) 0.026 0.252 0.252 0.046 
2.50x10-5 
Symbiont (-) 0.003 0.800 0.800 0.136 
1.25x10-5 
Symbiont (-) 0.039 0.046 0.046 0.346 
The untreated mycobacteria didn’t have countable plates at the 1.25x10-5 dilution 
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Appendix G-Probability Values of Symbiont (-) Coelomic Fluid Treated 
Average Mycobacterial Concentration Against Symbiont (+) Coelomic Fluid 
Treated and Untreated Average Mycobacterial Concentration Between 
Different Dilutions 
Dilution and 
Treatment 
1.00x10-4 
Symbiont (-) 
5.00x10-5 
Symbiont (-) 
2.50x10-5 
Symbiont (-) 
1.25x10-5 
Symbiont (-) 
1.00x10-4 
Mycobacterium 
Alone 
0.874 0.035 0.002 0.002 
5.00x10-5 
Mycobacterium 
Alone 
0.060 0.847 0.353 0.495 
2.50x10-5 
Mycobacterium 
Alone 
0.355 0.698 0.419 0.560 
1.00x10-4 
Symbiont (+) 0.812 0.026 0.003 0.039 
5.00x10-5 
Symbiont (+) 0.013 0.252 0.004 0.150 
2.50x10-5 
Symbiont (+) 0.026 0.800 0.409 0.538 
1.25x10-5 
Symbiont (+) 0.004 0.046 0.136 0.346 
The untreated mycobacteria didn’t have countable plates at the 1.25x10-5 dilution 
 
Appendix H-Probability Values of Mean Percent Survival of Symbiont (+) 
Treated Mycobacteria Between Different Dilutions 
Dilution and 
Treatment 
1x10-4 
Symbiont (+) 
5x10-5 
Symbiont (+) 
2.5x10-5 
Symbiont (+) 
1.25x10-5 
Symbiont (+) 
1.00x10-4 
Symbiont (+) --- 1.000 0.593 0.411 
5.00x10-5 
Symbiont (+) 1.000 --- 0.596 0.046 
2.50x10-5 
Symbiont (+) 0.593 0.596 --- 0.416 
1.25x10-5 
Symbiont (+) 0.411 0.046 0.416 --- 
Differences were found by Games-Howell (lack of heterogeneity of variances 
p=0.005) 
 
 
	 103	
 
 
 
Appendix I-Probability Values of Mean Percent Survival of Symbiont (-) 
Treated Mycobacteria Between Different Dilutions 
Dilution and 
Treatment 
1.00x10-4 
Symbiont (-) 
5.00x10-5 
Symbiont (-) 
2.50x10-5 
Symbiont (-) 
1.25x10-5 
Symbiont (-) 
1.00x10-4 
Symbiont (-) --- 0.985 0.115 0.479 
5.00x10-5 
Symbiont (-) 0.985 --- 0.122 0.282 
2.50x10-5 
Symbiont (-) 0.115 0.122 --- 0.019 
1.25x10-5 
Symbiont (-) 0.479 0.282 0.019 --- 
All p-values were found by Tukey HSD testing. 
 
 
Appendix J- Probability Values of Mean Percent Survival of Symbiont (+) 
and (-) Treated Mycobacteria Between Different Dilutions  
Dilution and 
Treatment 
1.00x10-4 
Symbiont (-) 
5.00x10-5 
Symbiont (-) 
2.50x10-5 
Symbiont (-) 
1.25x10-5 
Symbiont (-) 
1.00x10-4 
Symbiont (+) 0.812 0.514 0.122 0.128 
5.00x10-5 
Symbiont (+) 0.832 0.394 0.135 0.008 
2.50x10-5 
Symbiont (+) 0.308 0.347 0.851 0.173 
1.25x10-5 
Symbiont (+) 0.142 0.013 0.075 0.346 
All p-values were found using a t-test accounting for lack of homogeneity of 
variances (Levene’s Test for Symbiont (+) p=0.005) 
 
